Article

B&L finishes purchase of new fluoroquinolone

Rochester, NY-Bausch & Lomb has completed the purchase of InSite Vision's ISV-403 compound for the treatment of ocular infections. Bausch & Lomb gave InSite Vision an undisclosed cash sum and reimbursement of certain product development expenses. In exchange, InSite Vision will give Bausch & Lomb a percentage of future product sales in all licensed countries.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Related Content
New company OpZira formed following Alcon’s acquisition of LumiThera
September 16th 2025

New company OpZira formed following Alcon’s acquisition of LumiThera

Commercial real estate and your practice, part two with Colin Carr
September 16th 2025

Commercial real estate and your practice, part two with Colin Carr

Barti Software raises $12M Series A funding for AI-powered electronic health records for eye care
September 16th 2025

Barti Software raises $12M Series A funding for AI-powered electronic health records for eye care

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
September 16th 2025

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Bascom Palmer Eye Institute ranked as top ophthalmology hospital in US for 22nd year in a row
September 16th 2025

Bascom Palmer Eye Institute ranked as top ophthalmology hospital in US for 22nd year in a row

Most patients support AI in health care if it means more time with doctors
September 16th 2025

Most patients support AI in health care if it means more time with doctors

© 2025 MJH Life Sciences

All rights reserved.